Develops carbohydrate-based drug candidates that target galectin proteins for patients with liver disease and certain cancers.
10-K for FY2025, filed Mar 31, 2026We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease…View ↗
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
10-Q for Q3 FY2026, filed Nov 16, 2026
−$3.5MView ↗
8-K, filed Aug 14, 2026
Registrational Phase 3 trial protocol submission for belapectin in advanced MASH cirrhosis with portal hypertension is anticipated in 3Q…View ↗
8-K, filed Jun 23, 2026
Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to…View ↗
Loading...